Nurix Therapeutics (NRIX) had the highest return on June 25 by a mid-cap US stock, returning 15.8%.

ASSET	DATE	% RETURN
Nurix Therapeutics (NRIX)	6/25/2026	15.77%
Alamar Biosciences, Inc Common Stock (ALMR)	6/25/2026	12.57%
Abcellera Biologics (ABCL)	6/25/2026	9%
CG Oncology, Inc Common stock (CGON)	6/25/2026	8.31%
GeneDx (WGS)	6/25/2026	8.11%
Oceaneering International (OII)	6/25/2026	7.86%
Delek US Energy (DK)	6/25/2026	7.5%
WaterBridge Infrastructure LLC (WBI)	6/25/2026	7.35%
Pulse Biosciences (PLSE)	6/25/2026	7.27%
MaxLinear (MXL)	6/25/2026	7.21%
Praxis Precision Medicines (PRAX)	6/25/2026	7.13%
Definium Therapeutics (DFTX)	6/25/2026	6.67%
Haemonetics (HAE)	6/25/2026	6.55%
DPC (DPC)	6/25/2026	6.55%
NeoGenomics (NEO)	6/25/2026	6.43%
BlackBerry (BB)	6/25/2026	6.38%
Newell Brands (NWL)	6/25/2026	6.32%
Archrock (AROC)	6/25/2026	6.15%
Maravai Lifesciences Holdings (MRVI)	6/25/2026	6.07%
PBF Energy (PBF)	6/25/2026	6.02%
Par Pacific (PARR)	6/25/2026	6.01%
Hinge Health (HNGE)	6/25/2026	6%
Agilysys (AGYS)	6/25/2026	5.94%
Atmus Filtration Technologies (ATMU)	6/25/2026	5.88%
USA Compression Partners (USAC)	6/25/2026	5.77%

Mid-cap stocks are treated as having a market cap between $2B and $10B.